Four weeks of rapamycin raised brain blood flow only in people carrying APOE4

The comparison group in this trial was other people taking the same drug ^[2]. As the University of Missouri describes it, carriers and non-carriers both took a daily low dose for four weeks, and only the carriers' cerebral blood flow rose significantly ^[1]. That design shows the response depends on APOE4 status. It cannot show how much of the carriers' change the drug caused. That would take carriers on placebo, scanned over the same month. The account does not mention a placebo group, and it does not give the number of participants, the size of the blood-flow change or any side effects.

The account also claims more than the design supports. It says the genotype split demonstrates that the drug "acts directly upon the specific microvascular vulnerability induced by the variant" ^[12]. A different response in carriers is consistent with that idea. Demonstrating it would take direct measures of the vessels, and a blood-flow reading sits downstream of many things.

The choice of target is sound. APOE4 is the strongest known genetic risk factor for late-onset Alzheimer's: one copy triples lifetime risk, and two copies can raise it twelvefold ^[10]. Carriers often have restricted blood flow to memory regions long before amyloid plaques or tau tangles form ^[11]. So perfusion is a quantity a trial can move and measure within weeks. The most encouraging part is that the human result points the same way as the animal work before it, with the effect confined to the genotype the transgenic mice were built to model ^[8].

The sex difference ^[3] comes with a ready explanation in the account: women make up nearly two-thirds of Alzheimer's diagnoses ^[4]. That is a good reason to make sex a pre-planned comparison in a larger trial. For now it is a subgroup result from a pilot study ^[1].

The thing this doesn't tell you is whether more blood flow means less dementia. The account's summary says the trial establishes that vascular deficits "can be therapeutically modified decades before clinical dementia symptoms appear" ^[14]. Four weeks of imaging shows that one measure moved. It does not show that the change outlasts the pills, or that it slows plaque, tangle or memory changes years later. Rapamycin is an FDA-approved immunosuppressant, prescribed mainly to prevent organ transplant rejection ^[9]. A prevention regimen would mean giving it to people with no symptoms at all ^[5].

Ai-Ling Lin, the Mizzou professor who led the study ^[7], stated the goal with a hedge of her own. "Alzheimer's tends to happen more in older people, especially for those with APOE4," Lin said. "If we can slow down aging in the brain for those people most at risk, maybe we can reduce the risk of them developing Alzheimer's disease." ^[13]